Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report by Takeshi Kuroda et al.
Kuroda et al. BMC Research Notes 2014, 7:229
http://www.biomedcentral.com/1756-0500/7/229CASE REPORT Open AccessEffects of a biologic agent in a patient with
rheumatoid arthritis after treatment for
methotrexate-associated B-cell lymphoma:
a case report
Takeshi Kuroda1,2*, Hiroe Sato2, Takeshi Nakatsue2, Yoko Wada2, Shuichi Murakami2, Masaaki Nakano3
and Ichiei Narita2Abstract
Background: Several studies have suggested an increased risk of malignant tumor in patients with rheumatoid
arthritis. It has been also reported that rheumatoid arthritis patients have a high incidence of lymphoma compared
with the general population, and that patients receiving methotrexate, which is the anchor drug for rheumatoid
arthritis treatment, can develop lymphoproliferative disease. Nevertheless, management of rheumatoid arthritis after
treatment for methotrexate-associated lymphoma has not been fully investigated. We here report a patient with
rheumatoid arthritis who developed malignant lymphoma associated with methotrexate therapy. Moreover, we
describe the use of a biologic agent for a rheumatoid arthritis patient after treatment for lymphoma associated
with methotrexate.
Case presentation: A 60-year-old Japanese man with a 20-year history of rheumatoid arthritis was admitted to our
hospital with a left inguinal tumor. Open biopsy was performed and a biopsy specimen revealed diffuse large B-cell
lymphoma. As our patient had received methotrexate for 4 years, we diagnosed the lymphoproliferative disease as
being methotrexate-related. This lymphoma was not associated with Epstein- Barr virus by Epstein-Barr virus-encoded
ribonucleic acid in-situ hybridization, but this patient was an Epstein-Barr virus carrier, regarding serological testing. The
lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin,
vincristine, and prednisone/prednisolone therapy. Two years later, however, rheumatoid arthritis activity gradually
increased and was not controlled with salazosulfapyridine. Etanercept was administered in view of its possible effect
on B-cells, and this reduced the level of disease activity without recurrence of lymphoma.
Conclusion: The management of rheumatoid arthritis after treatment for methotrexate-associated lymphoma has
not been fully investigated yet. Etanercept appeared to be safe because of its B-cell effect, but further observation is
necessary to make a firm conclusion. Further accumulation of cases is needed to clarify which biologics are safe and
effective for treatment of methotrexate-associated B-cell lymphoma.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by painful swollen joints, impaired
mobility of the affected joints and permanent damage to
the cartilage and bone. Methotrexate (MTX) is an an-
chor drug in the treatment of RA, and has been shown
to delay the progression of radiographic changes in the
joints, halt worsening of the quality of life, and prolong
the life span of patients with RA [1,2].
However, a proportion of patients receiving MTX ther-
apy may develop potentially life-threatening adverse
events such as interstitial pneumonia [3-9], severe bone
marrow suppression [10,11] and lymphoproliferative dis-
ease (LPD), including malignant lymphoma [12-15].
Until now, there has been some debate over whether
MTX therapy for RA patients is associated with an in-
creasing risk of developing lymphoma [16-18].
Here we report a patient with RA who sequentially de-
veloped diffuse large B-cell lymphoma (DLBCL) during
a 4-year course of MTX therapy. We also discuss the
clinical effects and safety of biologics after treatment of
lymphoma.
Case presentation
A 60-year-old Japanese man with a 20-year history of RA
was admitted to our hospital with a left inguinal tumor in
May 2011. His family history included no consanguinity or
collagen diseases. He had first developed polyarthralgia
in March 2003, and visited our satellite hospital. A diag-
nosis of RA was made, based on the presence of sym-
metrical polyarthritis involving the hands, elbows and
knees, and positivity for serum rheumatoid factor (RF).
Initially he was treated with bucillamine (100 mg/day) and
prednisolone (2.5 mg/day), but this was soon switched to
salazosulfapyridine (500 mg/day). His RA disease activity
temporarily subsided, but later flared up again in May
2007. In June 2007, MTX was substituted for salazosulfa-
pyridine at the dose of 6 mg/week. Treatment with tacroli-
mus was added in December 2008 at a dose of 1 mg daily,
and was soon increased to 2 mg daily. Tacrolimus was
switched to mizoribine (100 mg/day) in March 2009, be-
cause the arthritis was not controlled. Therefore, the dose
of MTX (8 mg/week) was increased along with mizoribine
(8 mg/week) in November 2011. The patient showed
gradual resolution of his articular symptoms in response
to MTX.
In April 2011, he noticed a mass about 3 cm in diam-
eter in his left inguinal region, and this increased rapidly
in size over the next month. Abdominal contrast com-
puted tomography (CT) revealed a mass, approximately
7.0 cm in diameter, in the left inguinal region and in-
volving the external iliac vein (Figure 1). Additionally,
there was a thrombus in the distal part of the left exter-
nal iliac vein: therefore, he was referred to our hospitalon May 31. While scheduled to undergo a biopsy of the
mass, he was admitted on May 31. At that time, there
was no evidence of active synovitis.
On physical examination, his blood pressure was
120/62 mmHg with a regular heartbeat of 80 bpm and
a temperature of 36.0°C. Pulse oximetry showed an
oxygen saturation of 98%. Cardiac, lung and abdominal
examination revealed no abnormalities. Marked left foot
edema was observed. Neurological examination revealed
no abnormalities. There was symmetric polyarthritis in the
proximal interphalangeal and metacarpophalangeal joints
of the hand, wrist, and ankle. Laboratory studies revealed a
leukocyte count of 5740 per mm3, a red blood cell count of
387 × 104 per mm3, a hematocrit of 39.2%, hemoglobin
12.7 g/dL, platelet count 22.9 × 104 per mm3, and a C-
reactive protein level of 11.35 mg/dL. Electrolytes were
normal with a total protein level of 7.1 g/dL and hypoalbu-
minemia (2.9 g/dL). The blood urea nitrogen concentration
was 13.0 mg/dL, and the serum creatinine level was
0.68 mg/dL. Urinalysis showed a urinary protein excretion
of 0.1 g/day, and no hematuria. His level of RF was
127.0 IU/mL and anti-cyclic citrullinated peptide antibody
was 801.8 U/mL; antinuclear antibodies were negative.
Blood tests revealed the following values: alanine trans-
aminase 90 IU/L, aspartate aminotransferase 71 IU/L,
alkaline phosphatase 608 IU/L, lactate dehydrogenase
394 IU/L, glutamyl transaminase 187 IU/L, total biliru-
bin 2.8 mg/dL, total cholesterol 196 mg/dL, and trigly-
ceride 113 mg/dL. The serum immunoglobulin (Ig)
levels were as follows: IgG: 1171 mg/dL; IgA: 401 mg/
dL; IgM: 65 mg/dL. The serum carcinoembryonic anti-
gen level was 1.5 ng/mL (normal range, 1.0–6.7 ng/mL),
squamous cell carcinoma antigen level 0.5 ng/mL (normal
range, <1.5 ng/mL), carbohydrate antigen-125 24.0 ng/mL
(normal range, <35 ng/mL), α-fetoprotein 3.0 ng/mL (nor-
mal range <10 ng/mL), prostate specific antigen 0.54 ng/
mL (normal range <3.0 ng/mL), and carbohydrate antigen
19-9 5 U/mL (normal range, <37 U/mL). The soluble
interleukin-2 receptor level was elevated to 1168 U/mL
(normal range, 220–530 U/mL). Notably, serum IgG reac-
tion with Epstein-Barr virus (EBV)-viral capsid antigen
(VCA) was positive (1/160), serum IgA reaction with EBV
VCA was negative (<1/10), serum IgM reaction with EBV
VCA was negative (<1/10), serum IgG reaction with EBV-
early antigen (EBV-EA) was negative (<1/10), serum IgA
reaction with EBV-EA was negative (<1/10), and that with
the nuclear antigen was positive (1/20) (normal range, <1/
10). Additionally, chest X-ray showed no abnormalities.
A CT scan of the abdomen and chest showed no asci-
tes and no lymphadenopathy except for the left inguinal
tumor with involvement of the left external iliac artery.
Histological analysis of a biopsied lymph node revealed
DLBCL with cluster of differentiation (CD) 20+, CD3-
and negativity for EBV-encoded ribonucleic acid (EBER)
Figure 1 Abdominal contrast computed tomography revealed that a mass, approximately 7.0 cm in diameter (black arrows), was
detected in the left inguinal region and the tumor involved the external iliac vein (white arrow).
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showed a pathological cell phenotype of CD19+, CD20+,
CD22+, CD5-, CD10- and B-cell type. Cytogenetic ana-
lysis detected 45, X, -Y [3] /46, XY [17], indicating dele-
tion of chromosome Y. After diagnosis of lymphoma,
the patient received six courses of chemotherapy (R-
CHOP: rituximab, cyclophosphamide, adriamycin, vin-
cristine, prednisone). After the first chemotherapy cycle,
his foot edema began to improve and the left inguinal
tumor suddenly became non-palpable. CT scans of the
abdomen and chest taken in July 2011 revealed complete
resolution of the lymph node enlargement, and complete
remission of the DLBCL. He was discharged from hospital
in July 2011, and followed up as an outpatient. His RA
activity then gradually increased with symmetrical poly-
arthritis involving the hands, elbows and knees, and
therefore salazosulfapyridine (1000 mg/day) and pred-
nisolone (10 mg/day) were readministered. The RA dis-
ease activity became temporarily quiescent, but later
flared up again in March 2013. Therefore, in May 2013,
etanercept was added at 25 mg twice a week without
MTX to control the arthritis, and thereafter the RA ac-
tivity gradually improved. The disease activity score 28-
erythrocyte sedimentation rate (DAS28-ESR) was 2.8 in
August 2013 without any side effects or recurrence of
the lymphoma.
Conclusions
Several studies have suggested an increased risk of ma-
lignant tumor in patients with RA [19-21], but the ma-
jority of reports have noted that the risk is not increased
to a significant degree [22-26]. Whether or not RA pa-
tients treated with MTX have an increased risk of deve-
loping lymphoma remains a matter of controversy. It has
been reported that RA patients have a high incidence of
lymphoma compared with the general population, andthat patients receiving MTX, which is the anchor drug for
RA treatment, can develop LPD [12]. The risk of ma-
lignant lymphoma in patients with RA has been estimated
to be 1.9–6.7 times that in the general population
[20,21,24,26,27]. Recently, several reports have suggested
that EBV infection might be related to LPD associated
with MTX [13,28]. EBV is a B-lymphocytotropic virus
causing a variety of B-cell disorders, including infectious
mononucleosis and LPD in patients who are immunosup-
pressed. Moreover, other reports have indicated that many
spontaneous malignant lymphomas have become attenu-
ated by withdrawal of MTX treatment alone [29,30].
These reports clearly indicate that MTX induces LPD.
However, the relationship between the duration of MTX
treatment and the onset of LPD [18,31] still remains un-
clear. Several epidemiological studies have failed to find
any overall association between MTX exposure and the
development of lymphoma in RA patients [18,32-34]. By
contrast, it has been reported that the risk of lymphoma is
higher in RA patients with high disease activity [35]. Thus,
it is considered that MTX treatment reduces the disease
activity of RA, leading to suppression for LPD, whereas
MTX treatment induces LPD and EBV-related LPD in im-
munosuppressed patients. With regard to the histopatho-
logical type of lymphoma, a previous report has revealed
that 78% of RA patients have B-cell lymphoma, 5% have
T–natural killer-cell lymphoma, and 6% have Hodgkin’s
disease; 48% of B-cell malignant lymphomas in RA pa-
tients were been identified as DLBCL, which is the most
common form [35]. In our patient the lymphoma was di-
agnosed as DLBCL and the disease activity of RA could
not be sufficiently controlled. As our patient had received
MTX for 4 years, we diagnosed the LPD as being MTX-
related. This lymphoma was not associated with EBV by
EBER-ISH, but this patient was an EBV carrier, regarding
serological test.
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sociation between anti-TNF therapy and malignant lymph-
oma was also unclear. Several reports have indicated that
patients receiving anti-TNF antibody therapy had no sig-
nificantly increased risk of developing malignant lymph-
oma [21,36]. However, another report has indicated that
patients receiving anti-TNF antibody therapy had a signifi-
cantly higher incidence of lymphoma than patients without
anti-TNF antibody therapy [37]. According to a meta-
analysis of nine large-scale clinical trials involving RA pa-
tients, the risk of developing a malignant tumor was 3.3
times higher than in controls [38]. There was considerable
variation among individual cases, but the situation was
complicated by several factors, and epidemiologic trends
were unclear. After treatment for malignant lymphoma,
our patient achieved complete remission with rituximab,
but the disease activity of RA gradually became higher
again. In this case, we determined that MTX was contra-
indicated and administered salazosulfapyridine first, but it
was not effective. Therefore we decided to use biologics.
The rationale for treatment of lymphoma with a TNF in-
hibitor is still unclear. Although a direct action of TNF or
anti-TNF on B-cells has been hypothesized, no increase in
survival or apoptosis has been found [18,39]. Anti-TNF
agents can be structurally classified into two types; one
type is generated as an antibody against human TNF-α
and the other type is engineered from human TNF re-
ceptors. The former type includes infliximab, adalimu-
mab, and golimumab, and the latter type is etanercept.
Biologic treatments are known to affect B-cells. Anti-
TNF antibodies such as infliximab and adalimumab show
complement-dependent cytotoxicity (CDC), antibody-
dependent cell-mediated cytotoxicity (ADCC), and
outside-to-inside signaling (apoptosis/cell cycle arrest)
via transmembrane TNF-α, whereas etanercept has only
ADCC activity and lacks CDC activity and outside-to-
inside signaling via transmembrane TNF-α in vitro [40].
Transmembrane TNF-α is also known to exert unique
biologic functions such as cytotoxic activity and polyclonal
B-cell activation, in a cell-to-cell contact manner. Toci-
lizumab, an anti-interleukin-6 receptor inhibitor, reduces
the frequency of peripheral preswitching and post-switch
memory B-cells [41]. For this reason, we did not choose
tocilizumab for the present patient. Additionally, it has
been reported that both abatacept [42], a fusion protein
composed of immunoglobulin fused to the extracellular
domain of cytotoxic T-lymphocyte antigen 4, and certoli-
zumab pegol [43], a humanised anti-TNF pegylated Fab’
fragment do not mediate CDC and ADCC. Considering
the features of these biologics and the fact that our patient
had DLBCL with B-cell surface markers, we thought that
etanercept would be safer than other biologics. Our pa-
tient achieved low disease activity without recurrence of
malignant lymphoma after 5 months of treatment. If theresponse with etanercept is lost, abatacept or certolizumab
pegol might be chosen.
Here we have described the use of a biologic agent for
an RA patient after treatment for B-cell lymphoma asso-
ciated with MTX. We chose etanercept for our patient
considering its influence on B-cells, and he achieved low
disease activity. Etanercept appeared to be safe because
of its B-cell effect, but further observation is necessary
to make a firm conclusion. Further accumulation of
cases is needed to clarify which biologics are safe and ef-
fective in this situation.
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